Taysha Gene Therapies, Inc.
TSHA
$2.31
-$0.07-2.94%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -14.61% | 26.40% | -21.96% | 13.02% | -150.40% |
| Total Depreciation and Amortization | -6.91% | 3.40% | -8.70% | -0.92% | -11.20% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 36.34% | -70.79% | 180.64% | -7.03% | 106.04% |
| Change in Net Operating Assets | -75.16% | 55.78% | -37.37% | -1,536.91% | 106.15% |
| Cash from Operations | -20.28% | 15.30% | -0.52% | -8.62% | -22.84% |
| Capital Expenditure | -19,000.00% | 105.71% | 82.59% | -43.57% | -723.53% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -36.36% | -- | -- | -- | -- |
| Cash from Investing | -2,953.85% | 137.14% | 82.59% | -43.57% | -1,300.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -90.46% | 270,980.77% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -4,333.33% | 102.36% | -876.92% | 72.92% | 87.20% |
| Cash from Financing | 85.43% | -105.41% | -90.64% | 320,409.09% | 99.48% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -20.32% | -23.89% | -130.87% | 344.30% | 2.04% |